Niraparib in patients with newly diagnosed advanced ovarian BRCAm cancer: a post hoc

Redondo reports institutional grants from PharmaMar, Roche, and Eisai; and advisory roles at PharmaMar, AstraZeneca, GlaxoSmithKline, and Roche. [...] González-Martín reports consulting or advisory roles at Amgen, AZ, Clovis, GlaxoSmithKline, Genmab, Mersana, Roche, MSD, ImmunoGen, Sotio, and Takeda; speakers’ bureau compensation from AZ, Clovis, GlaxoSmithKline, Roche, and MSD; institutional research funding from Roche and GlaxoSmithKline; and travel support from GlaxoSmithKline, Az, and Roche. [...] Sabatier reports institutional grants from Eisai and AstraZeneca; personal fees from Roche, Pfizer, GlaxoSmithKline, Novartis, and AstraZeneca; and nonfinancial support from Roche, Pfizer, AstraZeneca, and Amgen. [...] In 49 patients with midline tumors the bilateral detection rate on LSG and perioperatively was 63 % and 74%, whereas the unilateral detection rate on LSG and perioperatively was 94% and 96 %. [...] In conclusion a combined fluorescent and radioactive tracer for SN procedure is feasible, and the additional use of NIRF imaging may improve the accuracy of SN identification in VC patients.